GlaxoSmithKline S.A.E (EGX:BIOC)

Egypt · Delayed Price · Currency is EGP

62.38

-1.66 (-2.59%)

At close: Feb 22, 2026

64.76% (1Y)

Market Cap	5.28B +60.8%
Revenue (ttm)	3.74B +33.3%
Net Income	98.36M -17.7%
EPS	1.17 -18.3%
Shares Out	83.51M
PE Ratio	53.95
Forward PE	n/a
Dividend	1.00 (1.60%)
Ex-Dividend Date	Jan 12, 2026

Volume	25,937
Average Volume	71,296
Open	64.04
Previous Close	64.04
Day's Range	62.05 - 64.94
52-Week Range	32.66 - 81.50
Beta	0.88
RSI	43.44
Earnings Date	Mar 5, 2026

About GlaxoSmithKline S.A.E

GlaxoSmithKline S.A.E engages in production of pharmaceutical chemicals. The company is involved in manufacture of general and specialty medicines, and vaccines. GlaxoSmithKline S.A.E was founded in 1981 and is based in London, the United Kingdom. GlaxoSmithKline S.A.E operates as a subsidiary of Glaxo Group Limited. [Read more]

Industry Pharmaceutical Preparations

Founded 1981

Employees 800

Stock Exchange Egyptian Stock Exchange

Ticker Symbol BIOC

Full Company Profile

Financial Performance

In 2024, GlaxoSmithKline S.A.E's revenue was 2.99 billion, an increase of 33.51% compared to the previous year's 2.24 billion. Earnings were 173.98 million, an increase of 187.78%.

Financial Statements